Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

Columnist Ben Hofmeister reflects on the feelings of guilt that surfaced after writing that his present vehicle no longer met his needs.

Scientists studying animals at high altitudes discovered a previously unknown mechanism that is key for regulating myelin ...

The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

Guest writer Kevin Byrne explains "Garage Dayz," his ambitious cycling project dedicated to fellow members of the MS ...

Columnist Desiree Lama is reconnecting with her love of plants and being outside after starting an outdoor garden at her new ...

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

Guest columnist Lindsay Kelly says that receiving her husband Rhead's MS diagnosis gave her a helpful framework for ...

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...

The decision to get an MS-accessible minivan didn't come easy, says columnist Ben Hofmeister, but it has proved to be the right one.

Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...